Clinical Mass Spectrometry: Innovative Solution for Diverse Medical Applications
Clinical mass spectrometry serves as a quantitative and qualitative analytical tool for assessment of complex mixtures in all the phases of drug development, including identification of the lead compound and their conformational details. Clinical laboratories use automation for the management of large number of samples through, either total automation systems or high level analyzer automation that are offered by clinical mass spectrometers such as Matrix Assisted Laser Desorption/Ionization (MALDI-TOF). These automated platforms assist effective processing of increasingly large workloads. Thus, clinical laboratories are among the largest end users of this technique. Moreover, the advancement in technology over the recent past, has enabled the ease of measuring and distinguishing separate contributions of molecules such as thyroid hormones and 25-hydroxyl vitamins D2 and D3. Application of translational research in the field of mass spectrometry has resulted in the discovery of blood-based biomarkers, endogenous metabolites, tumor markers, and new disease biomarkers. These advancements are expected to fuel adoption of clinical mass spectrometry devices.
Clinical diagnostic mass spectrometers have the capacity to analyze a limited range of samples such as biomarkers, proteins or drug molecules at once, even in cases of low concentrations thus, making them a valuable tool for diagnostic medical laboratories. Furthermore, it allows researchers to determine pharmacokinetic profiles of drugs that are administered in microdoses. The technology shift from traditional systems to high-resolution technologies such as the Quadrupole-Time of Flight (Q-TOF) mass spectrometry is expected to grow rapidly due to its benefits of accuracy, improved resolution, and sensitivity for clinical diagnostic applications.
The global clinical mass spectrometry market is estimated to be valued at US$ 4,982.5 million in 2017 and is expected to witness a CAGR of 7.3% over the forecast period (2017 – 2025).
Figure 1. Global Clinical Mass Spectrometry Market Share, By Product Type (%)
Increasing demand for automation in diagnostic techniques to drive growth of the clinical mass spectrometry market
Mass spectrometry enables various diagnostic analyses and study of functional genomics, metabolomics, and proteomics that facilitate development of a cost-effective analytic platform for analysis of samples. The automated laboratory systems provide several high-end functionalities such as MassEXTEND primer extension and nano liter dispensing of samples on to the spectroCHIPS, and data analysis using pre-loaded workstations that make the task of the clinicians and testing personnel easy and less tedious. Ease of management, quick results, and less complex functionality of these facilities are associated with low costs. Apart from cost- effectiveness, improved quality assays, simplicity, automation, and data reliability, increased sensitivity, reduced cross-reactivity & non-specific binding, and significantly low downtime are advantages offered by mass spectrometers over conventional immunoassays. Moreover, major capital investments associated with the set up and maintenance of these devices poses as a major restraint for the global market growth. Mass spectrometers are largely unaffordable for small diagnostic clinics and laboratories, especially in emerging economies. Moreover, these mass spectrometry methods are labor intensive and require technically skilled professionals. The dearth of these skillful operators is also a constraint for the global clinical mass spectrometry market growth.
Technological advancements leading to new product launch is a prominent factor fueling growth of the clinical mass spectrometry market
Advancements in technology includes miniaturization of mass spectrometry instruments and increasing automation of the entire spectrometric unit to reduce human efforts and improve efficiency of the instruments. The fully automated analyzer launched by Thermo Fisher in June 2017, is a step closer to achieve entirely automated systems in the mass spectrometry market that can be customized easily to be compatible with the laboratory information systems.
North America held the maximum share of clinical mass spectrometry market in 2016, owing to the presence of major key players and strategic collaborations. The second largest market share is provided by Europe. Under the Federation of analytical Chemistry and Spectrometry Societies, American Society for Mass Spectrometry was formed in 1969, with over 7,500 scientists working together to make advancements in the clinical applications of mass spectrometry and allied topics in academic, industrial, and governmental laboratories. This in turn, creates a strong network of research base in North America thus, contributing to swift growth of the clinical mass spectrometry market. Asia Pacific is also expected to grow at a substantial rate due to increased investments in R&D by various players and government bodies along with the introduction of new in-house manufacturing and R&D facilities.
Clinical mass spectrometry plays a vital role in the drug discovery pipeline for the development of personalized medicines. It is further used for live imaging of biological tissue samples for detection of biomarkers. Cost reduction and improved assay quality has driven the adoption of mass spectrometry. The American Association for Clinical Chemistry (AACC), states that the greater specificity of liquid chromatography–mass spectrometry-(LC MS) enables the measuring of testosterone for patients with low endogenous concentrations. This technique is more reliable than traditional immunoassays, especially for women and children. This led to the early adoption of the most recent generation of instruments using an established technology in the laboratories.
Clinical mass spectrometry offers significant advantages related to clinical research and forensic toxicology applications in terms of speed, robustness, simplicity, and selectivity of small molecules. Clinical mass spectrometry manufacturers are continuously collaborating with clinical diagnostic companies to retain the market share for new products that can quantify low trace levels of disease biomarkers. In Cambridge (U.S.) Thermo Fisher is advancing proteomics and clinical translational research through collaborations at the Biomarkers Research Initiatives in mass spectrometry center. Furthermore, increasing demand for clinical mass spectrometry to perform diagnostic assays in the field of endocrinology, toxicology, leukemia, and biochemical genetics, which helps overcome limitations of conventional immunoassays is also expected to create a favorable environment for growth of the market over the forecast period.
This report segments the global clinical mass spectrometry market on the basis of product type, application, and end user. On the basis of product type, the market is segmented into gas chromatography–mass spectrometry-(GC MS) instrument, liquid chromatography–mass spectrometry-(LC MS) instrument, maldi TOF mass spectrometer, capillary electrophoresis–mass spectrometry, and ion mobility spectrometry-mass spectrometry. Applications of clinical mass spectrometry include clinical testing, proteomics, and drug discovery. On the basis of end user, the clinical mass spectrometry market is segmented into research laboratories, diagnostic laboratories, and hospitals.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 34 market data tables and 27 figures on "Clinical Mass Spectrometry Market - Global forecast to 2025”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.